Examples of using Hirobriz in English and their translations into Polish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Hirobriz Breezhaler capsules must always be stored in the blister,
Hirobriz Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators.
Hirobriz Breezhaler should not be given to children
Hirobriz Breezhaler must not be used in people who are hypersensitive(allergic)
Hirobriz Breezhaler is used to keep the airways open in adults with chronic obstructive pulmonary disease COPD.
Talk to your doctor or pharmacist before using Hirobriz Breezhaler if you have asthma in this case you should not use Hirobriz Breezhaler.
Hirobriz Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease COPD.
Hirobriz Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD.
It is unlikely that Hirobriz Breezhaler will affect your ability to drive
If you have questions about how long to continue your treatment with Hirobriz Breezhaler, talk to your doctor or pharmacist.
An increase in the daily dose of Hirobriz Breezhaler beyond the maximum dose of 300 microgram is not appropriate.
Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Hirobriz Breezhaler at recommended therapeutic doses see section 5.1.
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease COPD.
Hirobriz Breezhaler is not indicated for the treatment of acute episodes of bronchospasm,
Hirobriz Breezhaler should only be used during pregnancy if the expected benefits outweigh the potential risks.
The 24-hour bronchodilator effect of Hirobriz Breezhaler was maintained from the first dose throughout a one-year treatment period with no evidence of loss in efficacy tachyphylaxis.
There are no data available for use of Hirobriz Breezhaler in patients with severe hepatic impairment.
Upon initiation of treatment with Hirobriz Breezhaler plasma glucose should be monitored more closely in diabetic patients.
Hirobriz Breezhaler should not be used in asthma due to the absence of long-term outcome data in asthma with Hirobriz Breezhaler.
Overall, the effects of the 150 and 300 microgram doses of Hirobriz Breezhaler were similar,